Auxesis Pharma develops the next generation of topical treatments based on research in dermatology, veterinary medicine and advanced formulation technology.
Our pipeline includes both human and veterinary development projects with the aim of treating pain, irritation and skin-related conditions directly where the problem occurs.
A pharmaceutical development track for the medical treatment of seborrhoeic keratoses.
Derivexa™ is a topical drug candidate being developed for the local treatment and removal of seborrhoeic keratoses.
Before
TreatmentA topical drug candidate for local pain treatment without an intended central opioid effect.
Opirexa™ is a pharmaceutical development project based on loperamide and is being developed for targeted treatment of local skin- and wound-related pain.
Advanced skincare with a scientific foundation.
Cutivelle is being developed as a platform for targeted products addressing skin changes, pigmentation and sensitive skin.
Local treatment where pain and irritation occur.
Lenvée is being developed for rapid and precise application in cases of local skin pain, irritation and redness.
Topical pain treatment for animals.
CoxyPet is being developed for the local treatment of pain, irritation and swelling in animals.
We develop science-based products with the aim of improving quality of life for people and animals — directly where the problem occurs.
All projects are currently under development. Safety, efficacy, formulation and regulatory pathways are evaluated within each respective development programme.